November 01, 2024
1 min watch
Save
VIDEO: Experts consider endpoints for clinical trials in geographic atrophy
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — In this video, Joan W. Miller, MD, chair of ophthalmology at Mass Eye and Ear, discusses highlights from the AAO meeting.
One topic that Miller found interesting centered on appropriate endpoints for clinical trials in geographic atrophy (GA).
“The bar has been set at an anatomic endpoint, so slowing down the growth of GA,” Miller said. “We accept that as specialists, but in the discussion, I think there was a lot of interest in having some other measure — a secondary endpoint that included some change in visual function.”
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Miller reports serving as a named inventor on patents and patent applications for ONL Therapeutics; serving as a consultant for ONL Therapeutics and Sumitomo Pharma Co.; serving in an advisory role for Drusolv Therapeutics; and receiving grant support from Lowy Medical Research Institute. Massachusetts Eye and Ear has a proprietary interest in photodynamic therapy and has received financial remuneration related to this technology. Miller reports receiving a share of the same in accordance with institutional guidelines.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.